AbbVie secured exclusive rights to ISB-2001, a trispecific antibody developed by IGI Therapeutics that simultaneously engages BCMA, CD38, and CD3 to treat relapsed/refractory multiple myeloma. The upfront payment is $700 million, with potential milestones exceeding $1.2 billion and royalties. The drug recently received orphan drug and fast track designations and demonstrated promising early-phase results with a 79% overall response rate. The collaboration extends across major markets including North America, Europe, Japan, and China, while Glenmark Pharmaceuticals handles emerging markets. AbbVie aims to leverage this multi-target biologic to improve efficacy and develop treatments beyond oncology into autoimmune diseases.